JP2014515742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515742A5 JP2014515742A5 JP2014502868A JP2014502868A JP2014515742A5 JP 2014515742 A5 JP2014515742 A5 JP 2014515742A5 JP 2014502868 A JP2014502868 A JP 2014502868A JP 2014502868 A JP2014502868 A JP 2014502868A JP 2014515742 A5 JP2014515742 A5 JP 2014515742A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- polypeptide
- nos
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 138
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 138
- 239000012634 fragment Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 34
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 25
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 23
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- 230000008021 deposition Effects 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 13
- 239000002254 cytotoxic agent Substances 0.000 claims description 12
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 10
- 201000001981 dermatomyositis Diseases 0.000 claims description 10
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 9
- 208000009292 Hemophilia A Diseases 0.000 claims description 9
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 9
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 9
- 206010047115 Vasculitis Diseases 0.000 claims description 9
- 230000000779 depleting effect Effects 0.000 claims description 9
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
- -1 N- maleimidopropionamido Chemical group 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 6
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 6
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 208000007475 hemolytic anemia Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 206010034277 Pemphigoid Diseases 0.000 claims description 5
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical group C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010006448 Bronchiolitis Diseases 0.000 claims description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 206010016717 Fistula Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000003782 Raynaud disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010052568 Urticaria chronic Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 201000010411 adult dermatomyositis Diseases 0.000 claims description 3
- 206010003230 arteritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 208000024376 chronic urticaria Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000002449 erythroblastic effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000003890 fistula Effects 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims description 3
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 3
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims description 3
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 2
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 241000282553 Macaca Species 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 102000048426 human CD37 Human genes 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- OWDQCSBZQVISPN-UHFFFAOYSA-N 2-[(2,5-dioxopyrrolidin-1-yl)amino]-4-(2-iodoacetyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-N 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 65
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- ZNALDVNNEBOGGN-UHFFFAOYSA-N n-(2,5-dioxopyrrol-1-yl)propanamide Chemical compound CCC(=O)NN1C(=O)C=CC1=O ZNALDVNNEBOGGN-UHFFFAOYSA-N 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470863P | 2011-04-01 | 2011-04-01 | |
| US61/470,863 | 2011-04-01 | ||
| PCT/US2012/031648 WO2012135740A2 (en) | 2011-04-01 | 2012-03-30 | Cd37-binding molecules and immunoconjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095431A Division JP2016145254A (ja) | 2011-04-01 | 2016-05-11 | Ｃｄ３７結合性分子及びその免疫複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515742A JP2014515742A (ja) | 2014-07-03 |
| JP2014515742A5 true JP2014515742A5 (OSRAM) | 2015-05-14 |
| JP6018622B2 JP6018622B2 (ja) | 2016-11-02 |
Family
ID=46932414
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502868A Expired - Fee Related JP6018622B2 (ja) | 2011-04-01 | 2012-03-30 | Ｃｄ３７結合性分子及びその免疫複合体 |
| JP2016095431A Pending JP2016145254A (ja) | 2011-04-01 | 2016-05-11 | Ｃｄ３７結合性分子及びその免疫複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095431A Pending JP2016145254A (ja) | 2011-04-01 | 2016-05-11 | Ｃｄ３７結合性分子及びその免疫複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9447189B2 (OSRAM) |
| EP (1) | EP2694105A4 (OSRAM) |
| JP (2) | JP6018622B2 (OSRAM) |
| KR (1) | KR20140031883A (OSRAM) |
| CN (2) | CN105999293B (OSRAM) |
| AU (2) | AU2012236210B2 (OSRAM) |
| BR (1) | BR112013025208A2 (OSRAM) |
| CA (1) | CA2831111A1 (OSRAM) |
| EA (1) | EA201391342A1 (OSRAM) |
| IL (1) | IL228537A0 (OSRAM) |
| MX (1) | MX2013011385A (OSRAM) |
| SG (1) | SG193447A1 (OSRAM) |
| WO (1) | WO2012135740A2 (OSRAM) |
| ZA (1) | ZA201307302B (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106046159B (zh) | 2010-03-12 | 2020-06-16 | 德彪发姆国际有限公司 | Cd37结合分子及其免疫缀合物 |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| US20160058884A1 (en) | 2014-09-02 | 2016-03-03 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
| WO2017122203A1 (en) * | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| KR102020706B1 (ko) | 2017-01-20 | 2019-09-11 | 주식회사 엘지화학 | 이차전지 분리막 내 수분함량 측정방법 |
| KR102706161B1 (ko) | 2017-03-31 | 2024-09-19 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CN110075315B (zh) * | 2018-01-26 | 2023-08-11 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联物及其制备方法和应用 |
| MX2020012755A (es) | 2018-05-30 | 2021-02-26 | Debiopharm Int Sa | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). |
| JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー．ブイ． | 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法 |
| EP3860715A1 (en) | 2018-10-04 | 2021-08-11 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| US20210388106A1 (en) * | 2018-10-26 | 2021-12-16 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CN111320690B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人Tim3单克隆抗体及其应用 |
| US20220226334A1 (en) * | 2019-05-21 | 2022-07-21 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody conjugate and application of pharmaceutical composition thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| EP4077391A1 (en) * | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| CN118339188A (zh) | 2021-09-21 | 2024-07-12 | 齐鲁普吉湾生物治疗公司 | 用于制备融合蛋白和双特异性抗体的异二聚体Fc |
| CA3235358A1 (en) | 2021-10-18 | 2023-04-27 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
| AU2023253796A1 (en) | 2022-04-14 | 2024-10-17 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates with improved pharmacokinetic and drug release properties |
| CN120209126B (zh) * | 2025-05-28 | 2025-09-16 | 中国医学科学院医学生物学研究所 | 人偏肺病毒单克隆抗体及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| AU2002243718B2 (en) | 2001-01-31 | 2007-12-06 | Biogen Idec Inc. | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP2005524386A (ja) | 2001-11-08 | 2005-08-18 | ▲養▼生堂有限公司 | 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用 |
| US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| WO2004045642A1 (en) | 2002-11-15 | 2004-06-03 | Immunomedics, Inc. | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| KR101412271B1 (ko) | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| SI1631313T1 (sl) * | 2003-06-05 | 2015-06-30 | Genentech, Inc. | Kombinirana terapija za B-celične motnje |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| WO2006085961A2 (en) | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| FR2880696B1 (fr) * | 2005-01-07 | 2007-08-24 | Ioltechnologie Production Sarl | Lentille intraoculaire photochromique |
| KR101363120B1 (ko) | 2005-02-10 | 2014-02-13 | 베일러 리서치 인스티튜트 | 항-인터페론 알파 모노클로날 항체 및 사용 방법 |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| US7601335B2 (en) * | 2005-05-20 | 2009-10-13 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| EP1904101A4 (en) | 2005-06-08 | 2011-06-15 | Univ Duke | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION |
| SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| HRP20140172T1 (hr) * | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| KR101479537B1 (ko) * | 2006-08-03 | 2015-01-07 | 백시넥스 인코포레이티드 | 항-ｉｌ-6 모노클로날 항체 및 이의 용도 |
| CN101646688A (zh) | 2006-10-24 | 2010-02-10 | 特鲁比昂药品公司 | 利用栗精胺提高抗体依赖性细胞毒性的方法 |
| US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| FI2155783T4 (fi) | 2007-04-03 | 2022-12-15 | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| EP2167130A2 (en) | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| GB2454915B (en) | 2007-11-23 | 2012-02-15 | Schlumberger Holdings | Spooling apparatus for well intervention system |
| WO2009085576A2 (en) | 2007-12-28 | 2009-07-09 | Spring Bioscience Corporation | Positive control cell pellets for immunohistochemistry and methods of use thereof |
| SG189772A1 (en) | 2008-04-11 | 2013-05-31 | Trubion Pharmaceuticals Inc | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US7740844B2 (en) | 2008-04-29 | 2010-06-22 | Taiwan Liposome Co. Ltd | Anti-VEGF monoclonal antibody |
| CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
| SG191679A1 (en) | 2008-06-16 | 2013-07-31 | Immunogen Inc | Novel synergistic effects |
| AR072804A1 (es) | 2008-07-15 | 2010-09-22 | Genentech Inc | Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales. |
| BRPI0921006A2 (pt) | 2008-11-13 | 2015-12-15 | Emergent Product Dev Seattle | terapias imunoterapêuticas combinadas de cd37 e usos destas |
| EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| WO2011100398A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
| CN106046159B (zh) | 2010-03-12 | 2020-06-16 | 德彪发姆国际有限公司 | Cd37结合分子及其免疫缀合物 |
| KR20130108069A (ko) | 2010-04-15 | 2013-10-02 | 알퍼 바이오테크, 엘엘씨 | Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도 |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| MX2014011745A (es) | 2012-03-30 | 2015-01-22 | Immunogen Inc | Metodos para aumentar la eficacia de terapia basada en cd37. |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015116729A2 (en) | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
| WO2015175533A2 (en) | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
-
2012
- 2012-03-30 EP EP12763324.6A patent/EP2694105A4/en not_active Withdrawn
- 2012-03-30 MX MX2013011385A patent/MX2013011385A/es not_active Application Discontinuation
- 2012-03-30 JP JP2014502868A patent/JP6018622B2/ja not_active Expired - Fee Related
- 2012-03-30 US US13/436,528 patent/US9447189B2/en not_active Expired - Fee Related
- 2012-03-30 AU AU2012236210A patent/AU2012236210B2/en not_active Ceased
- 2012-03-30 BR BR112013025208A patent/BR112013025208A2/pt not_active Application Discontinuation
- 2012-03-30 CN CN201610305409.3A patent/CN105999293B/zh not_active Expired - Fee Related
- 2012-03-30 SG SG2013069026A patent/SG193447A1/en unknown
- 2012-03-30 CN CN201280014646.4A patent/CN103596590A/zh active Pending
- 2012-03-30 CA CA2831111A patent/CA2831111A1/en not_active Abandoned
- 2012-03-30 EA EA201391342A patent/EA201391342A1/ru unknown
- 2012-03-30 KR KR1020137028942A patent/KR20140031883A/ko not_active Withdrawn
- 2012-03-30 WO PCT/US2012/031648 patent/WO2012135740A2/en not_active Ceased
-
2013
- 2013-09-29 IL IL228537A patent/IL228537A0/en unknown
- 2013-09-30 ZA ZA2013/07302A patent/ZA201307302B/en unknown
-
2016
- 2016-01-12 AU AU2016200175A patent/AU2016200175A1/en not_active Abandoned
- 2016-05-11 JP JP2016095431A patent/JP2016145254A/ja active Pending
- 2016-08-10 US US15/233,423 patent/US10556958B2/en not_active Expired - Fee Related
-
2020
- 2020-02-10 US US16/785,703 patent/US20200270361A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515742A5 (OSRAM) | ||
| JP5894912B2 (ja) | 抗ヒトｃｄ５２免疫グロブリン | |
| JP5841072B2 (ja) | Ｃｄ２０抗体およびその使用 | |
| KR101870277B1 (ko) | 특히, 대숙주성 이식편병(gvhd)을 예방하기 위한 항 cd4 항체 | |
| KR102771979B1 (ko) | 형질 전환 성장 인자-베타-반응성 폴리펩티드 및 이의 사용 방법 | |
| KR20200110358A (ko) | 항-pd-1 항체 및 치료 방법 | |
| US12187797B2 (en) | SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof | |
| JP2020513791A5 (OSRAM) | ||
| JP2008516970A5 (OSRAM) | ||
| JP2012526558A5 (OSRAM) | ||
| KR20140031883A (ko) | Cd37-결합 분자 및 그의 면역콘주게이트 | |
| JP2012500020A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| WO2007102200A1 (ja) | 抗ｃｄ２０モノクローナル抗体 | |
| JP2016507521A5 (OSRAM) | ||
| WO2010102792A2 (en) | Human antibodies against human fas and their use | |
| WO2022239820A1 (ja) | 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物 | |
| JP7486616B2 (ja) | Ｂｔｌａ抗体 | |
| US20250136707A1 (en) | Bispecific chimeric antigen receptors targeting cd20 and bcma | |
| JPWO2021163389A5 (OSRAM) | ||
| JP2015533374A5 (OSRAM) | ||
| JPWO2021186056A5 (OSRAM) | ||
| JP2013508391A5 (OSRAM) | ||
| CN113692286A (zh) | 一种用于免疫抑制的方法 |